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OBJECTIVES: SLE is an autoimmune disease with a broad list of differential mani-
festations, further complicating its diagnosis. The objective of this study was to
compare clinical outcomes, resource utilization and costs between patients with
earlier versus later SLE diagnosis.METHODS: Patients aged 18-64 years and at least
2 years of continuous coverage were identified from a large claims database be-
tween January 2000 and June 2010. Confirmed SLE diagnosis required 1 claim for
rheumatologist visits with a diagnostic code for SLE (ICD-9 code:710.0x) and, in
some cases, an additional requirement for  1 claim for a typical SLE medication.
All patients had 12months of continuous baseline eligibility prior to SLE diagno-
sis. SLE probable onset date was identified during the baseline period by the 2nd
claim for antinuclear antibody tests or prodromal symptoms of SLE. Patients were
stratified into Early or Late Diagnosis groups based on time between probable SLE
onset and diagnosis (6 or 6 months, respectively). Patients in each group were
propensity-score matched on age, gender, diagnosis year, region, and health plan
type. Resource use and costs were compared post-diagnosis between groups using
Poisson regression. Per-patient-per-month costs (PMPM) were calculated to ac-
count for differential lengths of SLE periods between groups. RESULTS: There were
4274 matched patients per group. Post-SLE diagnosis, the Early Diagnosis group
had lower rates of non-severe (RR0.95; 95% CI 0.94-0.96) and severe flares
(RR0.83; 95% CI 0.78-0.89)) and hospitalizations (RR0.72 (95% CI 0.68-0.77)) com-
pared to the Late Diagnosis group. Mean inpatient costs were lower for the Early
Diagnosis ($411 PMPM) patients compared to Late Diagnosis patients ($539 PMPM,
P-value0.001). Results were consistent for other cost categories. CONCLUSIONS:
Patients diagnosed with SLE sooner may experience lower flare rates, less health
care utilization and lower costs. This finding needs to be further explored within
the context of background SLE disease activity.
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UNITED STATES OUTPATIENT AND PHYSICIAN OFFICE VISIT PATTERNS
AMONG PSORIASIS PATIENTS RECEIVING ADALIMUMAB OR ETANERCEPT
Carter C1, Martin S2, Smith D3
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Centocor Ortho Biotech Services, LLC,
Horsham, PA, USA, 3IMS Health Consulting Group, Watertown, MA, USA
OBJECTIVES: Subcutaneous adalimumab or etanercept (SQ) used in moderate-to-
severe plaque psoriasis (PsO), may be patient self-administered in settings other
than that of a healthcare provider (HCP) or physician office. This study assessed the
annual number of office visits, over a 4.5-year period, incurred by PsO patients
receiving SQ and compared to PsO patients not receiving biologics (control).
METHODS: Adalimumab/etanercept claims received from the IMS LifeLink™ data-
base (01/01/2005-06/30/2010) were analyzed cross-sectionally and longitudinally.
Patients were aged 18 years at index and had 2 PsO diagnosis codes at anytime.
The cross-sectional analysis included patients with  1 claim for SQ and continu-
ous enrollment for the year of analysis. The longitudinal analysis included patients
with 6/12months pre-/post-index continuous enrollment, 2 SQ claims, 1 derm
visit, no other inflammatory conditions, and the PsO control group. RESULTS: A
total of 11,871 PsO patients receiving SQ (125,857 cumulative outpatient visits) were
included in the cross-sectional analysis (2005-2009). MeanSD HCP and dermatol-
ogy office visits spanned 8.99.1 to 10.29.8 and 2.66.2 to 4.08.0, respectively. A
total of 2,639 patients (27,684 cumulative outpatient visits) were included in the
longitudinal analysis. MeanSD HCP and dermatology office visits were 9.19.6
and 4.48.0, respectively. Mean (median) days between visits was 53.8 (44.3) and
94.0 (86.7) for HCPs and dermatology, respectively. The PsO control group (n38,727
patients) incurred a meanSD of 9.710.5 and 4.08.0 for HCPs and dermatology,
respectively. CONCLUSIONS: Since 2005, PsO patients receiving SQ had a mean of
9 HCP office visits each year. PsO patients, assessed longitudinally for 12 months
after SQ initiation, incurred a similar number of HCP office visits and visited der-
matologists on approximately a quarterly basis. Results were consistent with con-
trol group findings, suggesting that there are similar HCP visit patterns in PsO
patients using SQ and PsO patients not using biologics.
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RACIAL AND ETHNIC DIFFERENCES IN PATIENT PERCEPTIONS OF
INTRAVENOUS BIOLOGIC THERAPY AMONG CURRENTLY TREATED PATIENTS
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OBJECTIVES:Currently twomodes of administration are available for biologic ther-
apies used to treat immunology conditions: intravenous infusion (IV) and subcu-
taneous injection (SQ). This study explores patient perceptions of IV biologic ther-
apy for treatment of immunology conditions among patients of different
race/ethnicity. METHODS: Semi-structured telephone interviews were conducted
with 405 immunology patients currently treated with IV biologic therapy. Patients
identified preference for IV or SQ and reasons for preference. Patient perceptions
were assessed by agreement (6agree or 7strongly agree on a 7-point scale) with
a series of statements about mode of administration. RESULTS: The sample in-
cluded 83.5% (n338) Caucasian/White, 7.9% (n32) African-American/Black, and
5.2% (n21) Hispanic. While all patients preferred IV to SQ, African-American/
Black patients had a stronger preference than Caucasian/White patients (96.9% vs.
79.9%, p0.050). Of those preferring IV, a greater proportion of African-American/
Black patients reported not wanting to give self-injections or not liking needles as
a reason for IV preference (71.0% vs. 40.0% for Caucasian/White patients and 38.9%
for Hispanic patients, p0.050 for both). A significantly larger proportion of Afri-
can-American/Black patients agreed with the following statements than Cauca-
sian/White patients (p0.05 for all): IV medications are stronger than non-IVmed-
ications (50.0% vs. 31.7%); an IV infusion would be less painful than injections
(37.5% vs. 23.4%); I don’t like needles and therefore don’t like the idea of having to
give myself injections (46.9% vs. 24.0%); I would be concerned about the risk of
doing harm to myself if I had to give myself injections (40.6% vs. 16.3%); it is easier
for me to schedule an appointment at an infusion center than to remember when
to givemyself injections (37.5% vs. 17.2%).CONCLUSIONS: Patient perceptions of IV
biologic therapy differ by race/ethnicity. Coverage and access policies that limit
availability of IV biologic therapy may disproportionately affect racial/ethnic mi-
norities.
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OBJECTIVES: To assess how health-related quality of life (HRQOL) of patients with
myelodysplastic syndromes (MDS) who were red blood cell transfusion dependent
(RBC TD) at baseline and remained so across six months of treatment with Azaci-
tidine (AZA) compared with HRQOL of MDS patients who were RBC TD at baseline
but became RBC transfusion independent (TI) across sixmonths of AZA treatment.
METHODS: Data were collected in AVIDA®, a prospective registry of patients
treated with AZA. MDS patients who were RBC TD at baseline and who received 56
days or more of AZA were analyzed. RBC TD was verified centrally. Clinicians
provided data on clinical characteristics, including RBC transfusions. Patients com-
pleted the EORTC-QLQ-C30 at baseline and quarterly thereafter. Summary statis-
tics on global health status, functional scales, and symptom/other scales were
analyzed. Statistical significancewas determined byANOVA (SAS 9.1).RESULTS:At
baseline, 85 patients were RBC TD. At 6 months, 41 had achieved RBC TI, while 44
remained RBC TD. Baseline WHO Disease Classification, FAB subtype, IPSS Risk
level and HRQOL of patients who remained RBC TD were comparable and not
statistically different from those who became RBC TI. At six months, global health
status improved among those who became RBC TI, and declined among those who
stayed RBC TD (p0.0140). Statistically significant and clinically meaningful differ-
ences in change between baseline and 6 months were seen in physical and role
function (p0.0005 and p0.0154), but not in emotional, cognitive or social func-
tion. Fatiguewas the only symptom (of 9) in which changeswere different between
groups (p0.0285), with RBC TI patients reporting less fatigue, and RBC TD patients
reporting more. CONCLUSIONS: Findings from AVIDA® indicate that HRQOL
among RBC TD MDS patients treated with AZA improved significantly overall and
on certain domains when RBC TI was achieved.
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PAIN MANAGEMENT: OBSERVATION AND SIDE EFFECTS
Taieb C
CREES PFSA, Boulogne, France
OBJECTIVES: Pain treatment is a real challenge for Public Health and a requirement
for the quality and evolution of a health system. It responds primarily to a human-
ist and ethical objective, intrinsic to the dignity of the humankind. The physical
pain and moral suffering experienced during all ages of life make those already
weakened by the disease evenmore vulnerable. Treatment compliance is essential
to the efficacy of the treatment offered. Side effects or undesirable effects may be
caused by non compliance when they appear in the first 24 or 48 hours after treat-
ment. The objectyive is to describe the side effects perceived during the first 48
hours and spontaneously cited by the subjects treated with an analgesic.
METHODS: Prospective, longitudinal, multicenter observational study, conducted
in France using data collected by the general practitioners who agreed to
participate. RESULTS: Patients were treated either with a paracetamol-codeine
combination (n 742) or with a paracetamol-tramadol combination (n107). Nau-
sea / vomiting, dizziness, drowsiness and constipation were the 4 most commonly
cited side effects. In the first group, prevalence after 24h was 9.56%, 2.96%, 4.44%
and 1.08% respectively, versus 13.89%, 7.41%, 2.78%and 2.78% in the second group. On
the 2nd day, prevalence in the first group was 3.9%, 2.01%, 3.4% and 2.8% respectively,
versus11.1%, 3.7%, 1.85%and2.78% in thesecondgroup. Prevalenceofat leastoneside
effect perceived during the 7 days of treatment was 29.74% in the first group versus
40.74% in the second treatment group. CONCLUSIONS: A study published in 2005
(Patients and chronic pain–Exercer magazine January 2005-Le Goaziou et call) indi-
cated 37% constipation, 24% nausea and vomiting and 22.4% dizziness for a group
of patients undergoing treatment. It appeared that the patients treated with one of
the two drug combinations had fewer complaints of the same side effects.
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OBJECTIVES: The Nplate® NEXUS (NEXUS) Program included a registry of patients
in theUnited States tomonitor the long-termsafety and assure safe use ofNplate®.
Adverse events of special interest include changes in bone marrow reticulin for-
mation and collagen fibrosis, worsened thrombocytopenia after cessation of
Nplate®, thrombotic/thromboembolic complications, new hematologic malignan-
cies and progression of malignancy in patients with pre-existing hematological
malignancies or myelodysplastic syndromes (MDS), and medication errors associ-
ated with serious outcomes. METHODS: Data were collected through structured
questionnaires completed by healthcare professionals registered for the NEXUS
Program at baseline and every 6 months thereafter. RESULTS: Between August 22,
2008 and January 31, 2011, 5,235 patients (51% female, mean age 62 years, median
baseline platelet count 20x109/L) had enrolled in the NEXUS Program and received
Nplate®. The reported diagnoses were ITP (88.3%), other (8.9%), thrombocytopenia
from hematologic or lymphatic malignancies (1.1%), MDS (1.0%), and thrombocy-
topenia from chemotherapy (0.6%). Before entry, 86.1% of patients had received ITP
therapies, most commonly corticosteroids (61.8%), IVIG (55.4%), and rituximab
(42.5%). At baseline, 62.9% of patients were receiving concurrent ITP therapy, in-
cluding corticosteroids (43.8%), IVIG (17.7%), and rituximab (11.4%). Prior to enroll-
ment, 24.7% of patients had a splenectomy. As of December 2011, the FDA and
Amgen concluded that the restricted elements of the REMS could be eliminated.
CONCLUSIONS: The majority of patients in the NEXUS Program receiving Nplate®
were reported to have an ITP diagnosis with a history of previous ITP therapies and
were receiving concurrent ITPmedications. Further information regarding the data
from the NEXUS Program and the evolution of the REMS programwill be discussed.
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OBJECTIVES: Little is known about the characteristics of duloxetine patients initi-
ating therapy for chronic lower back pain (CLBP). This study identified demo-
graphic and clinical characteristics associated with initiation of duloxetine versus
other painmedications among CLBP patients.METHODS: Adult CLBP patients who
initiated medication therapy (duloxetine, anticonvulsants, antidepressants, mus-
cle relaxants, non-steroidal anti-inflammatory drugs [NSAIDs], opioids, or benzo-
diazepines) between November 1, 2010-March 31, 2011 were selected frommedical
and pharmacy claims from Medco Health Solutions. Treatment initiation was de-
fined as no pill coverage of themedication over the previous 90 days. The dispense
date of the first initiated medication was set as the index date. Comorbidities and
prior medication use was assessed during the 6 months before the index date.
Multiple logistic regression models were performed to identify predictors of initi-
ating duloxetine versus other pain medication. Separate models were estimated
with Charlson comorbidity index (CCI)  use of selected medications, and individ-
ual comorbidities  number of unique medications, respectively. RESULTS: We
identified 38,943 CLBP patients (mean age 58.0 years; 62.8 % female) who initiated
opioids (36.0%), NSAIDs (21.1%), muscle relaxants (13.6%), benzodiazepines (8.9%),
antidepressants (8.7%), anticonvulsants (7.5%), or duloxetine (4.1%). Patients who
initiated duloxetine had significantly higher CCI and more inpatient stays than
patients who initiated other pain medications except for anticonvulsants. The
regression results showed older patientswere less likely to initiate duloxetine than
anticonvulsants or opioids. Patients with higher CCI weremore likely to initiate on
duloxetine except for anticonvulsants and antidepressants. Prior use of pregabalin,
gabapentin, antidepressants, and benzodiazepines were associated with a higher
likelihood of initiating duloxetine. Patients who had more unique medications,
peripheral vascular disease, or depression were more likely to initiate duloxetine.
CONCLUSIONS: Presence of selected demographic characteristics, comorbidities
and prior use of medications were significant predictors of duloxetine initiation
among CLBP patients.
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FACTORS PREDICTING THE INITIATING DOSE OF DULOXETINE AMONG
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COMMERCIAL CLAIMS ANALYSIS
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OBJECTIVES: The purpose of this study was to identify the demographic and clin-
ical characteristics associated with the initiating dose of duloxetine among pa-
tients with chronic lower back pain (CLBP). METHODS: Medical and pharmacy
claims of CLBP patients who initiated duloxetine were analyzed. Initiation was
defined as no duloxetine coverage in the 90 days preceding the first duloxetine
prescription fill betweenNovember 1, 2010-March 31, 2011, Comorbidities and prior
medication use were assessed during 6 months prior to initiation (the index date).
Multiple logistic regressionmodels were estimated to identify predictors of initiat-
ing 60mg or 60mg versus 60mg, the recommended dose. RESULTS: 1,583 CLBP
patients (mean age 57.3 years; 69.2% female) who initiated duloxetine were iden-
tified. Common comorbidities were hypertension (47.6%) depression (37.2%) and
diabetes (21.1%). Opioids (79.7%) were the most commonly used pain medications
prior to duloxetine initiation, followed by antidepressants (54.6%) and muscle re-
laxants (40.9%). Regression results suggested that, patients 75 years were more
likely to initiate on a dose 60mg (Odds Ratio [OR]: 2.23, 95% confidence interval
[CI]: 1.46-3.38) and less likely to initiate on a dose60mg (OR: 0.39, 95% CI: 0.17-0.90)
than those 18-44 years old. Patients who used duloxetine in 6 months prior were
less likely to start on 60mg (0.64, 95% CI: 0.41-1.00), and more likely to start on
60mg (OR: 2.09, 95% CI: 1.29-3.39). Patients with prior use of opioid (OR: 0.71, 95%
CI: 0.54-0.95) or depression (OR: 0.75, 95% CI: 0.59-0.96) were less likely to initiate on
60mg, whereas patients with rheumatologic disease were more likely to start on
60mg (OR: 2.48, 95% CI: 1.34-4.59). CONCLUSIONS: A majority of CLBP patients
initiated duloxetine at 60mg/day. Presence of selected comorbidities and prior use
of medications were associated with certain initiating doses of duloxetine among
CLBP patients.
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DEVELOPMENT AND VALIDATION OF A CLASSIFICATION ALGORITHM FOR
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OBJECTIVES: To develop and validate an algorithm enabling the classification of
prophylactic (PPL) vs. on-demand (OD) factor VIII (FVIII) regimens for hemophilia A
(HA) patients in health insurance claims databases, thereby enabling the assess-
ment of these treatment approaches in real-world settings. METHODS: Prescrip-
tion records from two 2010-2011 US specialty pharmacy dispensing databaseswere
used. Males aged 2 years old with a HA diagnosis, 1 prescription for FVIII, no
anti-inhibitor agents ormixed PPL/OD FVIII regimenswere included. Four variables
common to specialty pharmacy and standard claims databases were used to de-
velop the algorithm: age at first observed dispensing (a weight proxy); total units of
FVIII dispensed (TUFVIII); and if TUFVIII data were not available, vial potency (IU/
vial) and number of vials dispensed were used to calculate TUFVIII dispensed (IU/
vial*number of vials dispensed). Different TUFVIII thresholds per age groups 2-12,
13-16, 17-27, and 28 formed the algorithm. Several TUFVIII thresholds for each
age group were iteratively tested over various observation lengths for patients
classified as on PPL (vs. OD) regimen. Each algorithm was assessed against actual
regimens prescribed based on physician notes using sensitivity, specificity, posi-
tive and negative predictive values (PPV & NPV). RESULTS: 445 patients were iden-
tified with 65% on PPL regimens. Patients receiving OD regimens were significantly
older than those receiving PPL regimens (Mean age [years] OD: 24.417.1; PPL:
19.613.0; p0.02). The best-performing algorithm was based on TUFVIII thresh-
olds of 43,920 (age group 2-12), 104,100 (13-16), 139,200 (17-27), and 176,970 (28),
over the first 12months of observation. Sensitivity, specificity, PPV, andNPV of this
algorithm were 0.81, 0.82, 0.89, and 0.71, respectively. CONCLUSIONS: The best-
performing algorithm showed promising performance validity with PPV0.89 for
ascertainment of PPL FVIII regimens in HA patients. Further refinement of the
classification algorithm on larger populations is needed.
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META-ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES –
METHODS FOR ENHANCING INTERPRETABILITY OF FINDINGS
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OBJECTIVES:Todescribe the available approaches for enhancing interpretability of
meta-analyses involving HRQL outcomes. METHODS: Narrative review of the
methodological literature. Application to two illustrative examples-one investigat-
ing the effect of interventions for respiratory rehabilitation in chronic obstructive
pulmonary disease (COPD), and one comparing pain in patients undergoing lapa-
roscopic cholecystectomy receiving dexamethasone or placebo. RESULTS: We
identified 12 approaches in 3 categories: 1) Summary estimates derived from the
pooled SMD: conversion to units of the most familiar instrument, or conversion to
risk difference or odds ratio. These approaches remain vulnerable to differential
variability in populations; 2) Summary estimates derived from the individual trial
summary statistics: conversion to units of the most familiar instrument or to ratio
of means. Both are appropriate complementary approaches to measures derived
from converted probabilities; and 3) Summary estimates derived from the individ-
ual trial summary statistics and established minimally important differences
(MIDs) for all instruments: presentation in MID units or conversion to risk differ-
ence or odds ratio. Risk differences are ideal for balancing desirable and undesir-
able consequences of alternative interventions. CONCLUSIONS: Use of these ap-
proaches may enhance the interpretability and the usefulness of systematic
reviews involving HRQL outcomes.
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USE OF MEDICAID ANALYTIC EXTRACT FOR EVALUATION OF DRUG USE AND
HEALTH SERVICES UTILIZATION IN PATIENTS WITH HEMOPHILIA
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OBJECTIVES: To evaluate the Medicaid Analytic Extract (MAX) database for use in
pharmacoepidemiologic research using hemophilia as a test case.METHODS: This
research was conducted using MAX data (years 2000-2004) for 49 states (excluding
AZ) and DC. We identified patients who received recombinant factor VIIa (rFVIIa),
factor VIII inhibitor bypass activity (FEIBA), factor VIII or factor IX or had a diagnosis
code for coagulation defects (ICD-9 286.xx). Use of antihemophilic drugs was iden-
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